Capital eventCH· 1mo ago
Walder Wyss Attorneys at Law | Oversubscribed USD 152 Million Series…
Vaderis Therapeutics secured a USD 152 million Series B funding to advance its global Phase 3 HEROIC trial of engasertib (VAD044) for hereditary hemorrhagic telangiectasia (HHT).
Intent
WARM· 55intent / 100
▸ why this score▾ score breakdown
- default: P(contract_to_capital_90d) · p=0.36 × w=3.0+1.1
- default: OON discount · × 0.75-0.4
- Final score (ambiguity-dampened) · default=55+55
- V2 winner: default · default=55+0
Go-to-market brief
Walder Wyss Attorneys
companyCH
Daily 5 RWA signals
Five signals in your inbox each morning. Email only.
Free. The daily 5 lands at 07:00 UTC, nothing else. One-click unsubscribe in every email.